M
Maria Grazia Franzosi
Researcher at Mario Negri Institute for Pharmacological Research
Publications - 133
Citations - 17641
Maria Grazia Franzosi is an academic researcher from Mario Negri Institute for Pharmacological Research. The author has contributed to research in topics: Myocardial infarction & Population. The author has an hindex of 46, co-authored 133 publications receiving 16304 citations. Previous affiliations of Maria Grazia Franzosi include University of Milan.
Papers
More filters
Journal ArticleDOI
Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study.
Salim Yusuf,Steven Hawken,Stephanie Ôunpuu,Leonelo E. Bautista,Maria Grazia Franzosi,Patrick J. Commerford,Chim C. Lang,Zvonko Rumboldt,Churchill L. Onen,Liu Lisheng,Supachai Tanomsup,Paul Wangai,Fahad Razak,Arya M. Sharma,Sonia S. Anand +14 more
TL;DR: Redefinition of obesity based on waist-to-hip ratio instead of BMI increases the estimate of myocardial infarction attributable to obesity in most ethnic groups.
Journal ArticleDOI
Early Protection Against Sudden Death by n-3 Polyunsaturated Fatty Acids After Myocardial Infarction Time-Course Analysis of the Results of the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico (GISSI)-Prevenzione
Roberto Marchioli,Federica Barzi,Elena Bomba,Carmine Chieffo,Domenico Di Gregorio,Rocco Di Mascio,Maria Grazia Franzosi,Enrico Geraci,Giacomo Levantesi,Aldo P. Maggioni,Loredana Mantini,Rosa Maria Marfisi,G. Mastrogiuseppe,Nicola Mininni,Gian Luigi Nicolosi,Massimo Santini,Carlo Schweiger,Luigi Tavazzi,Gianni Tognoni,Corrado Tucci,Franco Valagussa +20 more
TL;DR: In this article, the authors assess the time course of the benefit of n-3 polyunsaturated fatty acids (PUFAs) on mortality documented by the GISSI-Prevenzione trial in patients surviving a recent (<3 months) myocardial infarction.
Journal ArticleDOI
Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial
John W. Eikelboom,Lars Wallentin,Stuart J. Connolly,Michael D. Ezekowitz,Jeff S. Healey,Jonas Oldgren,Sean Yang,Marco Alings,Scott Kaatz,Stefan H. Hohnloser,Hans-Christoph Diener,Maria Grazia Franzosi,Kurt Huber,Paul A. Reilly,Jeanne Varrone,Salim Yusuf +15 more
TL;DR: In this article, the authors compared the risks of bleeding in the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial with dabigatran 150 and 110 mg twice a day and warfarin.
Journal ArticleDOI
Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: An analysis of the RE-LY trial
Lars Wallentin,Salim Yusuf,Michael D. Ezekowitz,Marco Alings,Marcus Flather,Maria Grazia Franzosi,Prem Pais,Antonio L. Dans,John W. Eikelboom,Jonas Oldgren,Janice Pogue,Paul A. Reilly,Sean Yang,Stuart J. Connolly +13 more
TL;DR: Results show that local standards of care affect the benefits of use of new treatment alternatives, and both doses at reducing intracranial bleeding versus warfarin were consistent irrespective of centres' quality of INR control.
Journal ArticleDOI
Benefit of Oral Anticoagulant Over Antiplatelet Therapy in Atrial Fibrillation Depends on the Quality of International Normalized Ratio Control Achieved by Centers and Countries as Measured by Time in Therapeutic Range
Stuart J. Connolly,Janice Pogue,John W. Eikelboom,Gregory C. Flaker,Patrick J. Commerford,Maria Grazia Franzosi,Jeff S. Healey,Salim Yusuf +7 more
TL;DR: For centers and countries, a target threshold TTR exists (estimated between 58% and 65%) below which there appears to be little benefit of OAC over antiplatelet therapy, and a wide variation exists in international normalized ratio control, as measured by TTR, between clinical centers and between countries.